Roles of Protein Post-Translational Modifications During Adipocyte Senescence

✅ 全文

蛋白质翻译后修饰在脂肪细胞衰老中的作用

作者 Min-Seon Hwang; Jingyeong Park; Yunha Ham; In Hye Lee; Kyung‐Hee Chun 期刊 International Journal of Biological Sciences 发表日期 2023 ISSN 1449-2288 DOI 10.7150/ijbs.86404 类型 原创研究 (Original Research)

📄 英文摘要 English Abstract

EN

Adipocytes are adipose tissues that supply energy to the body through lipids. The two main types of adipocytes comprise white adipocytes (WAT) that store energy, and brown adipocytes (BAT), which generate heat by burning stored fat (thermogenesis). Emerging evidence indicates that dysregulated adipocyte senescence may disrupt metabolic homeostasis, leading to various diseases and aging. Adipocytes undergo senescence via irreversible cell-cycle arrest in response to DNA damage, oxidative stress, telomere dysfunction, or adipocyte over-expansion upon chronic lipid accumulation. The amount of detectable BAT decreases with age. Activation of cell cycle regulators and dysregulation of adipogenesis-regulating factors may constitute a molecular mechanism that accelerates adipocyte senescence. To better understand the regulation of adipocyte senescence, the effects of post-translational modifications (PTMs), is essential for clarifying the activity and stability of these proteins. PTMs are covalent enzymatic protein modifications introduced following protein biosynthesis, such as phosphorylation, acetylation, ubiquitination, or glycosylation. Determining the contribution of PTMs to adipocyte senescence may identify new therapeutic targets for the regulation of adipocyte senescence. In this review, we discuss a conceptual case in which PTMs regulate adipocyte senescence and explain the mechanisms underlying protein regulation, which may lead to the development of effective strategies to combat metabolic diseases.

📄 中文摘要 Chinese Abstract

中文
脂肪细胞是通过脂质为机体提供能量的脂肪组织。脂肪细胞主要包括两种类型:储存能量的白色脂肪细胞(WAT)和通过燃烧储存脂肪产生热量的棕色脂肪细胞(BAT,即产热作用)。新出现的证据表明,脂肪细胞衰老的失调可能破坏代谢稳态,导致多种疾病和衰老。脂肪细胞在DNA损伤、氧化应激、端粒功能障碍或慢性脂质积累导致的脂肪细胞过度扩张等刺激下,通过不可逆的细胞周期停滞而进入衰老状态。可检测到的BAT量随年龄增长而减少。细胞周期调控因子的激活和脂肪生成调节因子的失调可能构成加速脂肪细胞衰老的分子机制。为了更好地理解脂肪细胞衰老的调控,研究翻译后修饰(PTMs)对于阐明这些蛋白质的活性及稳定性至关重要。PTMs是指在蛋白质生物合成后引入的共价酶促蛋白质修饰,如磷酸化、乙酰化、泛素化或糖基化。

📋 英文结构化总结 English Structured Summary

全文整理

EN

Background:

Adipocytes are adipose tissues that supply energy to the body through lipids. The two main types of adipocytes comprise white adipocytes (WAT) that store energy, and brown adipocytes (BAT), which generate heat by burning stored fat (thermogenesis). Emerging evidence indicates that dysregulated adipocyte senescence may disrupt metabolic homeostasis, leading to various diseases and aging. Adipocytes undergo senescence via irreversible cell-cycle arrest in response to DNA damage, oxidative stress, telomere dysfunction, or adipocyte over-expansion upon chronic lipid accumulation. The amount of detectable BAT decreases with age. Activation of cell cycle regulators and dysregulation of adipogenesis-regulating factors may constitute a molecular mechanism that accelerates adipocyte senescence. To better understand the regulation of adipocyte senescence, the effects of post-translational modifications (PTMs), is essential for clarifying the activity and stability of these proteins. PTMs are covalent enzymatic protein modifications introduced following protein biosynthesis, such as phosphorylation, acetylation, ubiquitination, or glycosylation.

Methods:

N/A - Review article

Results:

The review discusses a conceptual case in which PTMs regulate adipocyte senescence and explains the mechanisms underlying protein regulation. In adipose tissue, p53 contributes to insulin resistance in age-associated metabolic diseases. Excessive caloric intake exacerbates oxidative stress and increases the production of p53 and pro-inflammatory cytokines in adipose tissue. In contrast, p53 suppression in adipose tissue ameliorates senescence-like changes by reducing pro-inflammatory cytokines and improving insulin sensitivity. PPARγ controls adipocyte differentiation, inhibits cellular proliferation, and promotes cellular senescence. PPARγ induces the expression of p16INK4α (CDKN2A), a cell cycle inhibitor that promotes senescence, increases senescence-associated-β-galactosidase (SA-β-gal) levels, and triggers G1 arrest. Cellular senescence causes functional disorders of adipogenesis and lipid storage in adipose-derived stromal/progenitor cells. Browning (or beiging) of adipose tissue refers to the conversion of white adipocytes (WAT) into brown-like adipocytes, such as beige or brite cells. Brown adipocytes (BAT) are thermogenic. FOXA3 expression is increased in visceral fat during aging and has been reported to reduce BAT mass and the beiging capacity of WAT. Foxa3-knockout mice are long-lived, have increased BAT activity late in life, and are protected from age-related insulin resistance and high-fat diet-induced increases in visceral adiposity.

Data Summary:

The provided text does not contain explicit quantitative results or key statistics. Qualitative findings include that p53 suppression reduces pro-inflammatory cytokines and improves insulin sensitivity, and that Foxa3-knockout mice are long-lived with increased BAT activity. No numerical data (e.g., exact p-values, fold changes, or sample sizes) are presented in the extracted portion.

Conclusions:

Determining the contribution of PTMs to adipocyte senescence may identify new therapeutic targets for the regulation of adipocyte senescence. In this review, we discuss a conceptual case in which PTMs regulate adipocyte senescence and explain the mechanisms underlying protein regulation, which may lead to the development of effective strategies to combat metabolic diseases.

Practical Significance:

Understanding PTM regulation of adipocyte senescence may lead to the development of effective strategies to combat metabolic diseases, such as identifying new therapeutic targets for the regulation of adipocyte senescence.

📋 中文结构化总结 Chinese Structured Summary

中文

背景:

脂肪细胞是通过脂质为机体提供能量的脂肪组织。脂肪细胞主要包括两种类型:储存能量的白色脂肪细胞(WAT)和通过燃烧储存脂肪产生热量的棕色脂肪细胞(BAT,即产热作用)。新出现的证据表明,脂肪细胞衰老的失调可能破坏代谢稳态,导致多种疾病和衰老。脂肪细胞在DNA损伤、氧化应激、端粒功能障碍或慢性脂质积累导致的脂肪细胞过度扩张等刺激下,通过不可逆的细胞周期停滞而进入衰老状态。可检测到的BAT量随年龄增长而减少。细胞周期调控因子的激活和脂肪生成调节因子的失调可能构成加速脂肪细胞衰老的分子机制。为了更好地理解脂肪细胞衰老的调控,研究翻译后修饰(PTMs)对于阐明这些蛋白质的活性及稳定性至关重要。PTMs是指在蛋白质生物合成后引入的共价酶促蛋白质修饰,如磷酸化、乙酰化、泛素化或糖基化。

方法:

不适用——综述文章

结果:

本综述讨论了PTMs调控脂肪细胞衰老的概念性案例,并解释了蛋白质调控的潜在机制。在脂肪组织中,p53与年龄相关代谢疾病中的胰岛素抵抗有关。过量热量摄入加剧氧化应激,并增加脂肪组织中p53和促炎细胞因子的产生。相反,脂肪组织中p53的抑制可通过减少促炎细胞因子和改善胰岛素敏感性来减轻衰老样变化。PPARγ控制脂肪细胞分化、抑制细胞增殖并促进细胞衰老。PPARγ诱导细胞周期抑制因子p16INK4α(CDKN2A)的表达,该因子促进衰老、增加衰老相关β-半乳糖苷酶(SA-β-gal)水平并触发G1期阻滞。细胞衰老导致脂肪来源的基质/祖细胞中脂肪生成和脂质储存的功能紊乱。脂肪组织的褐变(或米色化)是指白色脂肪细胞(WAT)转化为棕色样脂肪细胞(如米色或褐色脂肪细胞)的过程。棕色脂肪细胞(BAT)具有产热功能。衰老过程中内脏脂肪中FOXA3表达增加,据报道其会降低BAT质量和WAT的米色化能力。Foxa3基因敲除小鼠寿命较长,晚年BAT活性增加,并可抵抗年龄相关的胰岛素抵抗和高脂饮食诱导的内脏脂肪增加。

数据摘要:

所提供的文本不包含明确的定量结果或关键统计数据。定性发现包括p53抑制可减少促炎细胞因子并改善胰岛素敏感性,以及Foxa3基因敲除小鼠寿命延长且BAT活性增加。提取部分未呈现数值数据(如精确p值、倍数变化或样本量)。

结论:

确定PTMs对脂肪细胞衰老的贡献可能为调控脂肪细胞衰老识别新的治疗靶点。在本综述中,我们讨论了PTMs调控脂肪细胞衰老的概念性案例,并解释了蛋白质调控的潜在机制,这可能为开发对抗代谢疾病的有效策略提供依据。

实际意义:

理解PTMs对脂肪细胞衰老的调控可能有助于开发对抗代谢疾病的有效策略,例如识别调控脂肪细胞衰老的新治疗靶点。

📖 英文全文 English Full Text

EN

Int. J. Biol. Sci. 2023, Vol. 19 Ivyspring International Publisher 5245 International Journal of Biological Sciences 2023; 19(16): 5245-5256. doi: 10.7150/ijbs.86404 Review

Roles of Protein Post-Translational Modifications During Adipocyte Senescence Min-Seon Hwang1, Jingyeong Park2, Yunha Ham2, In Hye Lee2,, and Kyung-Hee Chun1, 1. 2.

Department of Biochemistry & Molecular Biology, Graduate School of Medical Science, Brain Korea 21 Project, Institute of Genetic Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. Department of Life Science, College of Natural Science, Ewha Womans University, 52 Ewhayeodae-Gil, Seodaemun-gu, Seoul, 03760, Republic of Korea.

 Corresponding authors: In Hye Lee Ph.D., Department of Life Science, College of Natural Science, Ewha Womans University, 52 Ewhayeodae-Gil, Seodaemun-gu, Seoul, 03760, Republic of Korea. Tel: +82-2-3277-3032, E-mail: lih3026@ewha.ac.kr. Kyung-Hee Chun Ph.D., Department of Biochemistry & Molecular Biology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea. Tel: +82-2-2228-1699, Fax: +82-2-312-5041, E-mail: khchun@yuhs.ac. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2023.05.22; Accepted: 2023.09.27; Published: 2023.10.16

Abstract Adipocytes are adipose tissues that supply energy to the body through lipids. The two main types of adipocytes comprise white adipocytes (WAT) that store energy, and brown adipocytes (BAT), which generate heat by burning stored fat (thermogenesis). Emerging evidence indicates that dysregulated adipocyte senescence may disrupt metabolic homeostasis, leading to various diseases and aging. Adipocytes undergo senescence via irreversible cell-cycle arrest in response to DNA damage, oxidative stress, telomere dysfunction, or adipocyte over-expansion upon chronic lipid accumulation. The amount of detectable BAT decreases with age. Activation of cell cycle regulators and dysregulation of adipogenesis-regulating factors may constitute a molecular mechanism that accelerates adipocyte senescence. To better understand the regulation of adipocyte senescence, the effects of post-translational modifications (PTMs), is essential for clarifying the activity and stability of these proteins. PTMs are covalent enzymatic protein modifications introduced following protein biosynthesis, such as phosphorylation, acetylation, ubiquitination, or glycosylation. Determining the contribution of PTMs to adipocyte senescence may identify new therapeutic targets for the regulation of adipocyte senescence. In this review, we discuss a conceptual case in which PTMs regulate adipocyte senescence and explain the mechanisms underlying protein regulation, which may lead to the development of effective strategies to combat metabolic diseases. Keywords: Adipocyte, Senescence, Post-translational modification, Metabolic disease, Metabolic homeostasis

Introduction Adipogenesis is a key process during cell differentiation from pre-adipocytes to mature adipocytes. Adipocytes proliferate to form adipose tissue, where the energy harvested from food that exceeds the energy expenditure is stored as lipids. Pre-adipocytes develop in four stages: growth arrest, mitotic clonal expansion, early differentiation, and terminal differentiation into mature adipocytes [1]. In this process, pre-adipocytes accumulate lipids by increasing the quantities of enzymes needed for triglyceride (TG) synthesis and the accumulation of TG. Increased expression of transcription factors, such as peroxisome proliferator-activated receptor γ

(PPARγ), CCAAT/enhancer binding protein α (C/EBPα), and CCAAT/enhancer binding protein β (C/EBPβ), is essential for adipocyte differentiation [2] (Figure 1A). PPARγ is a significant regulator of adipogenesis, and the C/EBP family (α and β) is one of the most critical downstream targets of PPARγ. These proteins are also necessary for the transcription and expression of insulin receptors, adiponectin, adipocyte protein 2 (aP2), and adipokines in mature adipocytes [3, 4]. Understanding the processes involved in adipocyte senescence and their regulation is essential. Adipocyte senescence represents an irreversible cell https://www.ijbs.com

Int. J. Biol. Sci. 2023, Vol. 19 cycle arrest in response to various stressors, including DNA damage, oxidative stress, metabolic stress, and telomere shortening [5, 6] (Figure 1B). These stressors transmit signals through multiple pathways, most of which activate the cell cycle inhibitor p53. These pathways converge upon the activation of the cyclin-dependent kinase (CDK) inhibitors p16, p21, p27, and p15. Eventually, they activate retinoblastoma protein (RB), causing senescence [7]. Unrepaired DNA damage and the loss of repair capacity can induce senescence [8]. In adipose tissue, p53 contributes to insulin resistance in age-associated metabolic diseases. Excessive caloric intake exacerbates oxidative stress and increases the production of p53 and pro-inflammatory cytokines in adipose tissue. In contrast, p53 suppression in adipose tissue ameliorates senescence-like changes by reducing proinflammatory cytokines and improving insulin sensitivity [9]. Interestingly, PPARγ controls adipocyte differentiation, inhibits cellular proliferation, and promotes cellular senescence [10, 11]. PPARγ induces the expression of p16INK4α (CDKN2A), a cell cycle inhibitor that promotes senescence, increases senescence-associated-βgalactosidase (SA-β-gal) levels, and triggers G1 arrest [11]. Cellular senescence causes functional disorders of adipogenesis and lipid storage in adipose-derived stromal/progenitor cells [12] (Figure 1C). Browning (or beiging) of adipose tissue refers to the conversion of white adipocytes (WAT) into brown-like adipocytes, such as beige or brite cells (Figure 2). Brown adipocytes (BAT) are thermogenic, meaning they produce heat by burning stored fat. Adipose tissue browning is typically associated with

5246 increased energy expenditure and improved metabolic health. BAT, which are responsible for energy production, contain more mitochondria than do WAT which provide energy storage [13]. Developmentally, in mice, BAT originates from a myogenic factor 5 (MYF5)-positive mesoderm lineage [14] (Figure 2A). Transcriptional control of the BAT-specific thermogenic program is mediated by PPAR-γ coactivator 1-alpha (PGC-1α) and PR domain-containing 16 (PRDM16) [15] (Figure 2B). It is well established that BAT rely on mitochondrial function for maintaining intracellular metabolism. In addition, BAT mitochondria are functionalized by uncoupling protein-1 (UCP1), which allows the translocation of protons to dissipate energy during non-shivering thermogenesis [16, 17] (Figure 2B). Forkhead box protein A3 (FOXA3) expression is increased in visceral fat during aging and has been reported to reduce BAT mass and the beiging capacity of WAT [18, 19]. In the context of aging, it has been reported that mitochondrial enzyme expression is reduced in adipose tissue from old mice, yet little is known regarding the mechanisms that mediate these changes [20, 21]. Similarly, it is well-established that human WAT mitochondrial function, as measured by tissue oxygen consumption, is reduced in both obesity and aging [21]. Consistent with this, Foxa3-knockout mice are long-lived, have increased BAT activity late in life, and are protected from age-related insulin resistance and high-fat diet-induced increases in visceral adiposity [19] (Figure 2C). Evidence suggests that replicative capacity and UCP1 expression in BAT are significantly reduced during aging [16, 17]. In particular, the proliferative

Figure 1. Overview of differentiation and cellular senescence in adipocytes. (A) Adipogenesis, (B) senescence, and (C) induction of disease. Pre-adipocytes differentiate into mature adipocytes during adipogenesis. PPARγ and C/EBPα/β are regulators of adipogenesis, and their expression is increased. Also, insulin receptors, adiponectin, aP2, and adipokines are highly expressed in mature adipocytes. Stressors such as hyper-proliferation, DNA damage, oxidative stress, metabolic stress, and telomere shortening activate p53, CDK inhibitors, and RB, which induce senescence. During the accumulation of senescent cells, cell size increases, and free fatty acids (FFAs) are released at high levels with increased inflammation and collagen. Decreased adiponectin and poor insulin sensitivity also occur. These factors are related to cellular dysfunction and cause various diseases such as obesity, diabetes, chronic inflammation, and fibrosis.

Int. J. Biol. Sci. 2023, Vol. 19 capacity and UCP1 expression in response to cold stimuli appear to be abolished in aged BAT [22]. Increasing age of brite adipocytes progressively leads to the development of a WAT phenotype, which prevents adipocyte browning in older mice and humans [23, 24]. Conversely, the levels of the senescence markers p16 and p21 are highly increased during the senescence process in BAT [13, 25]. BAT thermogenesis declines with aging [26] (Figure 2D), consistent with the reduction in the thermogenic factor UCP1, whereas UCP1 levels in BAT are stabilized by SIRT5 desuccinylation. Sirt5 deficiency in BAT increases the succinylation of UCP1, resulting in decreased UCP1 stability and function, which impairs mitochondrial homeostasis and alters BAT-mediated thermogenesis [27]. This may thus be one of the mechanisms regulating BAT senescence. Some detrimental effects of senescent cell

5247 accumulation have been reported, including inflammation, insulin resistance in adipose tissue, underlying obesity, and type 2 diabetes [6, 7, 9, 28]. The senescence-associated secretory phenotype (SASP), which includes pro-inflammatory cytokines, is produced via autocrine and paracrine pathways to enhance and diffuse senescent cell influence and induce chronic inflammation in adipose tissues [29]. Under stress stimulation conditions, these interactive signaling pathways converge toward the activation of a transcriptional program managed by nuclear factor kappa B (NF-κB) and C/EBPβ, the core effectors that initiate and maintain SASP gene expression [30]. Removing senescent adipocytes mitigates inflammation and ameliorates insulin resistance in adipose tissue [29]. Therefore, the proper control of adipocyte senescence is critical for the management of various diseases.

Figure 2. Processes deciding adipocyte fate during differentiation and senescence, and their regulators in adipose tissues. Adipose tissue can be divided into white adipose tissue (WAT) and brown adipose tissue (BAT). (A) Through the differentiation of adipocytes, WAT and BAT develop from precursor cells, and Myf5 is expressed from the precursor cells. Pre-adipocytes turn into WAT and BAT during maturation, with transcription factors such as PPARγ, C/EBPs, and PRDM16 regulating this process. Browning of the adipose tissue leads to increased energy expenditure and improved metabolic health. Compared with WAT, BAT contains more mitochondria, which are related to energy production. The increased expression of PPARγ, C/EBPγ, and C/EBPγ is associated with WAT differentiation. (B) BAT is regulated by PGC-1α and PRDM16. Additionally, BAT mitochondria are functionalized by UCP1. With increased lipotoxicity, mitochondrial dysfunction, ROS, and DNA damage, adipocytes become senescent. (C) During senescence, FOXA3 expression is increased concomitant with reduced BAT mass and beiging capacity of WAT. (d) During BAT senescence, mitochondrial enzyme expression is reduced, as is UCP1 expression. In contrast, the expression levels of p16 and p21 are increased.

The mechanisms controlling cellular senescence can be divided into three categories. These include transcriptional modifications, such as DNA methylation at the genetic and epigenetic levels; mRNA-level regulatory mechanisms, such as mRNA stabilization or degradation; and post-translational modifications (PTMs), such as ubiquitination [31]. Here, we focused on PTMs that regulate protein stability and activation. PTMs such as phosphorylation, acetylation, ubiquitination, and glycosylation alter the chemical properties and functions of proteins [32]. Abnormal PTMs can cause biological dysfunction and lead to various diseases. For example, PTMs significantly affect the structure and function of proteins that regulate adipocyte senescence. Understanding the role of PTMs in adipocyte senescence may guide the discovery of new therapeutic targets to modulate adipocyte senescence. In this review, we summarize how the stability and activation of proteins involved in the induction of adipocyte senescence are regulated by various PTMs (Table 1) and provide new insights regarding the regulation of adipocyte senescence (Figure 3). Table 1. The summary of Post-translational Modification (PTM) in adipocyte senescence PTM Phosphorylation

P38 MAPK[40-42] Dephosphorylation PTEN[49-51] Deacetylation Ubiquitination SIRT1[57,58,62] SIRT6[64] HDAC1[70, 72] MKRN1[83-85] TRIM 23 TRIM 25[87] MARCH 5[88] [86] O-GlcNAcylation

Substrate Pathway SASP JAK/STAT pathway IRS-2 p38 MAPK signaling pathway PIP3 PI3K/AKT signaling pathway PPARγ Lipogenesis p27Kip1 Adipocyte differentiation H3K27 Thermogenesis p14ARF, Fatty acid AMPKα oxidation PPARγ Adipocyte differentiation

CRL4B[90] PPARγ MDM2[92] STEAP4 WWP1[94] p27Kip1 OGT, PPARγ, OGA[97, 100,102] HBP flux[103,104] C/EBPβ AMPKα Action site D3 Lys268 and Lys293 Lys100 Lys27

Glycolysis and basal mitochondrial respiration Adipocyte differentiation HIF1-α/PKM2 Lys18 and Lys161 signaling pathway Adipocyte differentiation Adipocyte Thr54 of the differentiation N-terminal activation function-1 domain Ser180 and Ser181 Fatty acid oxidation

Regulation of protein activation by phosphorylation Adipocyte senescence is tightly regulated to maintain energy and metabolic homeostasis [26]. Senescent cells accumulate in aging fat in response to replicative, cytokine-induced, and metabolic stresses [33]. Janus kinase (JAK), p38, and the phosphatase and tensin homolog on chromosome 10 (PTEN) upregulate adipocyte senescence under various cellular stress conditions. Cellular phosphorylation is known to potentiate or downregulate adipocyte senescence; however, the underlying mechanisms require further investigation.

JAK An increase in cellular senescence in response to intrinsic or extrinsic stresses and the broadly related SASP promote organismal aging and adipose tissue dysfunction [26, 34, 35]. Inhibition of the JAK/signal transducer and activator of transcription (JAK/STAT) pathway, which plays a significant role in adipose tissue development and function and regulates SASP, can partially inhibit SASP secretion [34, 36]. The JAK1/2 inhibitor ruxolitinib decreases the pro-inflammatory SASP in vitro and in vivo and enhances insulin sensitivity in aging mice [34]. Aging cell improvement enhances adipogenesis and metabolism [37, 38]. Activin A secreted by senescent cells, blocks adipogenesis. Treatment of aged mice and primary human senescent fat progenitor cells with a JAK inhibitor reduced activin A levels and restored lipid accumulation and expression of critical adipogenic markers. JAK inhibitors also reduce lipotoxicity and increase insulin sensitivity [37]. The inhibition of JAK activity is a strategy used to alleviate adipocyte cellular senescence by ameliorating senescent adipose progenitors and stem cells (APSCs).

p38 MAPK SASP is potentiated by the activation of p38 mitogen-activated protein kinase (MAPK), which is induced by increased NF-κB transcriptional activity. p38 MAPK inhibition markedly reduced the secretion of most SASP factors [34, 39]. SASP contributes to dysfunction in aged organs. Age-related adipose tissue changes increase pro-inflammatory cytokines, such as tumor necrosis factor α (TNF-α), promoting adipocyte senescence [3, 35, 40], which reduces brown adipogenic differentiation and promotes insulin resistance in BATs. During this cellular event, the serine residues of insulin receptor substrate 2 (IRS-2) are phosphorylated by p38 MAPK [40-42]. The inhibition of p38 MAPK decreases SASP secretion, which may ameliorate adipocyte senescence.

PTEN The insulin signaling response displays heightened sensitivity to cellular aging in adipocytes, https://www.ijbs.com Int. J. Biol. Sci. 2023, Vol. 19 5249

thereby decreasing the insulin response [6, 26, 43, 44]. PTEN is a phosphatidylinositol phosphate phosphatase that plays an essential role in various cellular processes, including genome maintenance, DNA repair, cell cycle control, proliferation, metabolism, migration, tumorigenesis, and senescence. One of the critical roles of PTEN is to inhibit insulin signaling [45-48]. PTEN negatively regulates insulin signaling by dephosphorylating phosphatidylinositol-3,4,5triphosphate (PIP3), resulting in decreased phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling [49]. Pten deficiency enhances energy expenditure in brown adipose tissue. PTEN loss and activation of PI3K/AKT signaling lead to an improved ability to handle metabolic stress in mice [50]. PTEN downregulation increased the proliferation of stromal vascular fraction (SVF) cells, including adipocyte progenitor cells, in adipose tissues. Pten deficiency restores the differentiation capacity of high-passage SVF cells and increases adipogenesis. In contrast, PTEN expression is upregulated during cellular senescence [51]. The regulation of PTEN activity and expression levels is a strategy for controlling adipocyte cellular senescence.

PPARγ directly interacts with and negatively regulates SIRT1 expression [10]. PPARγ acetylation, which is correlated with Sirt1 deficiency, increases during cellular senescence [10]. SIRT1 limits preadipocyte hyperplasia through c-Myc deacetylation, improves insulin sensitivity, reduces inflammation, and suppresses lipid accumulation by inhibiting PPARγ [57]. The proto-oncoprotein zinc finger and BTB domain-containing 7C (ZBTB7C) negatively regulate Sirt1 transcript levels. Its expression level is increased in the WAT of aging mice. ZBTB7C, a potent SIRT1 repressor, increases PPARγ acetylation [58]. Expression of nicotinamide phosphoribosyltransferase (NAMPT), which recycles NAD+, increases during cellular senescence. NAMPT activity promotes pro-inflammatory SASP [34, 59-61]. Age-related reduction in SIRT1 activity may be a critical mechanism in the loss of beige adipose tissue as well as in age-associated thermogenic impairment [26]. Upregulation of SIRT1 potentiates brown remodeling of subcutaneous WAT by deacetylation of PPARγ at Lys268 and Lys293 [62]. SIRT1 regulation is likely a key mechanism controlling adipocyte senescence.

Senescent adipocytes accumulate in aging fat in response to cytokines and metabolic stress [26, 33]. Adipocyte senescence is regulated in response to cold exposure-stimulated thermogenesis. The mitochondrial function and activity of UCP-1, a thermogenesisrelated mitochondrial protein in adipocytes, decrease with cellular aging. Additionally, the pro-inflammatory capacity of BAT increases with age [26, 35, 52]. Histone deacetylases (HDACs) such as sirtuin 1 (SIRT1), SIRT 6, and HDAC1 are essential regulators of adipocyte senescence under conditions of cellular stress [26, 53, 54]. Although SIRTs and HDAC1 are deacetylases, their roles in adipocyte senescence differ. SIRT1 and SIRT6 prevent adipocyte senescence, whereas HDAC1 potentiates adipocyte senescence. The number of brown and beige adipocytes decreases with age. Cellular deacetylation events regulate adipocyte senescence. However, the underlying mechanisms remain unclear.

SIRT1 A reduction in beige adipocyte formation has been detected in aging adipose tissues [26]. SIRT1, a nicotinamide adenine dinucleotide (NAD+)dependent deacetylase, drives beige adipocyte generation in WAT [26]. In addition, NAD+ levels, SIRT1 activity, and SIRT1 expression decrease with age and cellular senescence progression [10, 55, 56].

The essential roles of SIRT6 in adipocytes are the regulation of lipid metabolism and the prevention of inflammation. SIRT6 stimulates lipolysis, enhances adipose tissue browning, and ameliorates adipose tissue inflammation, thereby improving insulin action in the peripheral tissues [63]. SIRT6 promotes cell proliferation and antagonizes cellular senescence; however, SIRT6 expression decreases during cellular senescence [64]. Moreover, SIRT6 suppresses p27Kip1 (p27) expression during cellular senescence [64]. SIRT6 mediates the polyubiquitination of p27, directing its degradation by the proteasome and thereby regulating the acetylation status of p27. Thus, SIRT6 delays cellular senescence [64]. Aging and excessive caloric intake, which are two major risk factors for obesity and diabetes, lead to decreased SIRT6 levels [65]. Sirt6 deficiency in pre-adipocytes blocks adipogenesis and regulates mitotic clonal expansion [66]. Sirt6 deletion in adipose tissue impairs the thermogenic function of BAT, causing morphological ‘‘whitening’’ of brown fat, reduced oxygen consumption, obesity, decreased core body temperature, and cold sensitivity. Fat Sirt6-deleted mice exhibit increased blood glucose levels, severe insulin resistance, and hepatic steatosis. Moreover, Sirt6 deficiency inhibits WAT browning following cold exposure or β3-agonist treatment [67]. Taken together, these results indicate that SIRT6 plays a protective role against adipocyte senescence. https://www.ijbs.com

Int. J. Biol. Sci. 2023, Vol. 19 HDAC1 Inhibition of signaling pathways that induce SASP using HDAC inhibitors, including trichostatin A (TSA), suppresses senescence. At low concentrations, TSA acts as a pan-SASP blocker [34, 68]. TSA may decrease PPARγ expression [53, 69], potentiating cellular senescence. HDAC inhibitors are also involved in regulating thermogenic adipocyte differentiation, adaptive thermogenesis, and metabolic disorder pathogenesis [70]. HDAC1 is highly expressed in senescent cells [71]. HDAC1 negatively regulates the thermogenic program in BAT. Repression of HDAC1 promotes acetylation and prevents methylation of histone H3K27, which increases the expression of BAT-specific genes such as UCP1, PGC-1α, and PRDM16 [70, 72]. SIRT1 negatively regulates HDAC1 function [54, 73]. SIRT1 is degraded and downregulated during cellular senescence [56, 74], indicating that Sirt1 deficiency may increase HDAC1 activity in senescent cells [54]. Thus, regulation of HDAC1 function may improve adipocyte senescence.

Regulation of protein stability by ubiquitination: E3 ubiquitin ligases Another regulatory mechanism that influences physiological cellular senescence is the post-translational modification of cellular proteins through ubiquitination. The ubiquitin-proteasome pathway (UPP) regulates the differentiation of various cell types. Alterations in the UPP in mature adipocytes can potentially modulate adipose function during adipocyte aging [75]. Ubiquitin is activated by E1 and transferred to E2 or Ub conjugase. In turn, the E2 enzyme transfers ubiquitin to E3 or directly ubiquitinates the target protein in conjunction with E3 [72, 73]. Proteasome activity decreases during senescence, which may be associated with aging and age-associated diseases [75]. E3 ubiquitin-protein ligases are crucial factors in the regulation of senescence by ubiquitination. Knockdown of regulator of cullins-1 (ROC1), a component of the SKP, Cullin, F-box (SCF) E3 ubiquitin ligases, suppresses the growth of several human cell lines by inducing senescence [76]. In addition, the inactivation of the von Hippel–Lindau (VHL) tumor suppressor gene, which encodes a subunit of an E3 ubiquitin ligase, causes a senescence-like phenotype in human cancer cell lines [77]. Therefore, E3 ubiquitin ligase activity appears to be essential for regulating adipocyte senescence. Several E3 ligases have recently been found to be present in adipocytes, including seven in absentia homolog 2 (SIAH2), makorin ring finger protein 1 (MKRN1), tripartite motif protein 23

5250 (TRIM23), and neural precursor cell-expressed developmentally downregulated protein 4 (NEDD4) [78]. The ubiquitination pathway regulates p53 tumor suppressor stability, localization, and functions in normal cells [79]. E3 ubiquitin ligases, including murine double minute 2 (MDM2) and MKRN1, predominantly regulate p53 expression levels and activities under various physiological conditions [79, 80]. Overexpression of MDM2 and CDK4 can induce human telomere reverse transcriptase (hTERT) overexpression and p53 degradation in human 2H transgenic bone marrow-mesenchymal stem cells (BM-MSCs), increase cell proliferation and migration, and suppress the adipogenic differentiation potential in vitro [81].

MKRN1 In telomerase-positive cells, overexpression of MKRN1, an E3 ligase, promotes hTERT degradation, decreases telomerase activity, and subsequently decreases telomere length [82]. MKRN1 knockdown induces senescence by stabilizing p14ARF. MKRN1 also regulates SASP [83]. MKRN1 negatively regulates PPARγ via ubiquitin-mediated proteasomal degradation, with PPARγ2 and MKRN1 interacting directly [84]. MKRN1 also ubiquitinates and degrades AMPactivated protein kinase alpha (AMPKα) subunits, whereas MKRN1 depletion promotes glucose consumption and suppresses lipid accumulation via AMPK stabilization and activation [85]. These results suggest that the E3 ligase MKRN1 potentially regulates adipocyte senescence, warranting further studies.

TRIM23 and TRIM25 TRIM23 is an E3 ligase that can regulate PPARγ protein stability and mediate abnormal polyubiquitin conjugation [86]. TRIM23 is required to form late enhanceosomes and recruit Pol II during late adipogenic differentiation, whereas treatment with the proteasome inhibitor MG132 inhibits the reduction of PPARγ in TRIM23-knockdown cells [86]. The 26S proteasome does not readily recognize PPARγ aberrantly ubiquitinated by TRIM23, resulting in its protection from proteasomal degradation [86]. However, TRIM25 directly induces PPARγ ubiquitination and its proteasome-dependent degradation [87]. TRIM25 decreases PPARγ expression and inhibits 3T3-L1 adipocyte differentiation [87]. Therefore, TRIM25 expression is negatively correlated with PPARγ expression.

MARCH 5 The E3 ubiquitin ligase, membrane-associated RING-CH-type finger 5 (MARCH 5) regulates mitochondrial dynamics and is in turn regulated by https://www.ijbs.com

Int. J. Biol. Sci. 2023, Vol. 19 PPARγ in adipocytes undergoing adipogenesis [88]. MARCH 5 depletion increases glycolysis and basal mitochondrial respiration [88]. MARCH5-deficient cells display mitochondrial elongation and phenotypic changes owing to increased SA-β-Gal expression caused by cellular senescence [89].

CRL4B The aryl hydrocarbon receptor (AhR) reduces PPARγ protein stability through a proteasomedependent mechanism [90]. Overexpression of AhR in 3T3-L1 cells induced a decrease in endogenous PPARγ, which was reversed by treatment with MG132 [90]. AhR serves as a substrate receptor in the Cullin 4B-RING E3 ubiquitin ligase (CRL4B) AhR complex to induce polyubiquitination of PPARγ [90].

MDM2 MDM2, an E3 ubiquitin ligase, regulates adipogenesis by initiating adipocyte differentiation through the promotion of cAMP-mediated transcriptional activation of cAMP response element-binding proteins (CREB) and the induction of C/EBPδ expression [91]. High-fat diet (HFD)-fed Mdm2-adipocyte-specific knock-in (Mdm2-AKI) mice display epididymal white adipose tissue (eWAT) dysfunction, including senescence [92]. MDM2 suppresses six-transmembrane epithelial antigen of prostate 4 (STEAP4) expression via ubiquitin modification [92]. Revival of STEAP4 rescued MDM2-induced adipose dysfunction in eWAT of HFD-fed Mdm2-AKI mice [92].

WWP1 Obesity upregulates WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) in WAT. WWP1, which belongs to the NEDD4-like family of E3 ubiquitin ligases, is upregulated in obese WAT [93]. WWP1 induces p27Kip1 degradation via ubiquitination and inhibits p27Kip1-mediated replicative senescence [94]. WWP1 overexpression decreases reactive oxygen species (ROS) levels in 3T3-L1 cells, and WWP1 protects against obesity-associated oxidative stress in adipocytes and WAT [95].

Regulation of protein activation by O-GlcNAcylation O-linked-N-acetylglucosamination (O-GlcNAcylation), a post-translational glycosylation event, occurs on proteins in the nucleus, cytoplasm, and mitochondria, regulates cell signaling, and is associated with several pathological conditions [96]. O-GlcNAcylation is the single-sugar addition of O-linked-β-N-acetylglucosamine (O-GlcNAc) to the hydroxyl groups of the serine or threonine residues of

5251 target proteins [97]. The attachment and removal of O-GlcNAc from proteins are processed by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) [98]. O-GlcNAcylation is highly responsive to glucose, and insulin resistance enhances O-GlcNAcylation [99]. Increased levels of O-GlcNAcylation have been observed in response to the induction of adipocyte differentiation [100]. Post-translational modifications regulate OGT activity, and OGT activation occurs when tyrosine phosphorylation of OGT increases following insulin stimulation in 3T3-L1 cells [101]. Abnormal protein O-GlcNAcylation is essential for the development and progression of senescencerelated diseases [102]. O-GlcNAcylation levels increased significantly on and after day 5 of 3T3-L1 differentiation induction [100]. Simultaneously, C/EBPα and adiponectin expression, and lipid droplet size increased [100]. O-GlcNAcylation of vimentin, long-chain fatty acid-CoA, and pyruvate carboxylase increases with adipocyte differentiation [100]. Treatment with 6-diazo-5-oxo-norleucine (DON), a glutamine:fructose-6-phosphate amidotransferase (GFAT) inhibitor, blocked adipocyte differentiation at the stage of C/EBPα expression, which was associated with an overall increase in O-GlcNAcylation [100]. Therefore, it can be assumed that O-GlcNAcylation partially participates in adipogenesis. In 3T3-L1 adipocytes, O-GlcNAc causes post-transcriptional modification of PPARγ. The primary O-GlcNAc site of PPARγ is threonine 54 of the N-terminal activation function-1 domain [97]. In 3T3-L1 cells, an increase in O-GlcNAc modification mediated by the OGA inhibitor NButGT decreases PPARγ transcriptional activity and terminal adipocyte differentiation [97]. C/EBPβ is also modified by O-GlcNAc, which is present in nucleocytoplasmic proteins. GlcNAcylation sites (Ser180 and Ser181) are located in the regulatory domain and are extremely close to the phosphorylation sites (Thr188, Ser184, and Thr179) that regulate DNA-binding activity [102]. GlcNAcylation of Ser180 and Ser181 blocks the phosphorylation of Thr188, Ser184, and Thr179, thereby delaying adipocyte differentiation [102]. In contrast, the mutation of Ser180 and Ser181 to Ala increased C/EBPβ transcriptional activity [102]. Therefore, GlcNAcylation and phosphorylation appear to modulate the function of C/EBPβ by alternately occupying adjacent sites. The hexosamine biosynthesis pathway (HBP) flux functions as a nutrient sensor and induces O-GlcNAc modification of the AMPK α subunit in both immortal and primary murine adipocytes [103]. O-linked glycosylation via HBP flux regulates AMPK activation and induces fatty acid oxidation in 3T3-L1 https://www.ijbs.com

Int. J. Biol. Sci. 2023, Vol. 19 adipocytes [104] whereas removal of O-GlcNAc by hexosaminidase reduces AMPK activity [104]. Thus, HBP correlates with O-GlcNAc and is likely to affect adipocyte senescence.

Conclusions and perspectives Adipogenesis is the process of differentiation of pre-adipocytes into mature adipocytes. There are two main types of fat cells that contain lipids: WAT, which store energy, and BAT, which produces heat. Pre-adipocytes develop in four stages: growth arrest, mitotic clone expansion, early differentiation, and terminal differentiation into mature adipocytes [1]. In this process, increased expression of transcription factors is essential for adipocyte differentiation [2] (Figure 1A). Upon DNA damage, oxidative stress, metabolic stress, or telomere shortening, adipocytes undergo senescence and irreversible cell cycle arrest, thereby inhibiting adipogenesis [5, 6]. These cellular stressors activate p53 and induce CDK inhibitors and RB, which cause senescence [7]. In addition, the modification of adipogenesis regulators such as PPAR and C/EBPα/β results in adipocyte senescence. Moreover, mitochondrial UCP1 expression has been reported to decrease in old mouse adipocytes; however, little is known about this mechanism [16, 17, 27]. As UCP1 levels decrease during the aging of BAT, the levels of aging markers p16 and p21 increase significantly [13, 25]. In addition, the expression of UCP1, a thermogenesis factor, in BAT is stabilized by SIRT5 desuccinylation. This may thus be a mechanism by which BAT senescence is regulated; however, this possibility requires further investigation. Once lipids continuously accumulate in the adipose tissue, the adipocyte senescence rate increases and insulin sensitivity decreases, resulting in adipose tissue dysfunction. SASP induces chronic inflammation in adipose tissue. Cellular senescence causes lipid storage dysfunction. Thus, the appropriate control of fat cell aging is a viable strategy for preventing aging-related diseases. Although the underlying mechanisms remain poorly understood, adipocyte senescence is essential for diverse physiological processes, including metabolism and various age-related diseases. To better understand the processes of adipocyte senescence, it is important to identify the modulators of adipogenic factors, including PPARγ, and their regulatory molecular mechanisms, such as PTMs. PTMs are associated with oxidative stress, inflammation, and aging, thereby influencing aging characteristics [105]. Some PTMs participate in healthy aging, suggesting that they are essential regulators and predictive markers of the senescence process [106]. PTMs significantly affect

5252 aging by targeting epigenetic and non-epigenetic pathways. Therefore, understanding the role of PTMs in cellular senescence may advance the development of targeted therapies for age-related diseases. p38, JAK, and PTEN influenced fat cell senescence through phosphorylation under stress (Figure 3). Inhibition of the JAK/STAT pathway inhibits SASP secretion and Pten deficiency increases adipogenesis [34, 36-39]. SIRT1 induces beige adipocyte production in WAT [107]. PPARγ interacts directly with SIRT1 to negatively regulate SIRT1 expression [10]. NAMPT activity that rescues NAD+ promotes SASP. SIRT6 also inhibits p27 expression during cell aging, thereby slowing this process [34, 59-61]. SIRT1 and SIRT6 regulation is expected to be a key mechanism in controlling fat cell aging [63-65, 67]. Suppression of the SASP pathway inhibits aging. HDAC1 is highly expressed in older cells. Regulation of HDAC1 function may retard adipocyte aging (Figure 3). The inactivation of tumor suppressor genes can result in phenotypes similar to those observed during aging [77]. Therefore, E3 ubiquitin ligase activity appears to be essential for the regulation of adipocyte aging. MKRN1 may negatively regulate PPARγ through ubiquitination [84]. Because TRIM25 reduces PPARγ expression and suppresses the differentiation of 3T3-L1 adipocytes, TRIM25 correlates negatively with PPARγ expression [87]. MARCH 5 depletion increases glycolysis and basal mitochondrial respiration [88]. In addition, components of E3 ubiquitin ligases such as ROC1, TRIM23, CRL4B, WWP1, and MDM2 inhibit adipocyte senescence [76, 86, 90, 92, 95]. O-GlcNacylation regulates cell signaling and plays an essential role in the development and progression of age-related diseases. OGT and OGA regulate the attachment and removal of O-GlcNAc. In 3T3-L1 cells, these enzymes induce adipocyte senescence. We predict that new treatments for adipocyte senescence can be developed by understanding the involvement of PTMs in fat-cell aging (Figure 3). In particular, a clearer understanding is needed regarding how PTMs, including acetylation/deacetylation, phosphorylation, ubiquitination, and glycosylation, regulate the function of necessary adipogenic factors, such as PPAR (Figure 3). Finally, it is important to establish the degree to which prevention of adipocyte senescence mediates beneficial effects on adipose tissue in various disease conditions. Future research on the regulatory mechanisms underlying adipocyte senescence will likely provide critical insights regarding the new and complex networks involved in human biological processes, including aging and metabolism. https://www.ijbs.com

Figure 3. Regulation of cellular senescence in adipocytes by post-translational modification (PTM). PTM regulates adipocyte senescence through various physiological pathways, including phosphorylation, deacetylation, ubiquitination, and glycosylation. Inhibition of p38, JAK, and PTEN can alleviate senescence in adipocytes. Deacetylation also regulates adipocyte senescence. SIRT1 and SIRT6 are deacetylases that play protective roles against adipocyte senescence. SIRT1 negatively regulates HDAC1, which is highly expressed in senescent cells. TRIM23 and MDM2 are E3 ubiquitin ligases that induce adipocyte senescence. However, ROC1 suppress cellular senescence. The E3 ubiquitin ligases MKRN1, MARCH 5, TRIM25, CRL4B, and WWP1 are also potential regulators of adipocyte senescence. OGT and OGA regulate O-GlcNAcylation. Abnormal protein O-GlcNAcylation causes senescence-related diseases.

Abbreviations AhR: aryl hydrocarbon receptor; AMPK: AMP-activated protein kinase; aP2: adipocyte protein 2; BAT: brown adipocyte; CDK: cyclin-dependent kinase; C/EBPα/b: CCAAT/enhancer binding protein α/b; CREB: cAMP-mediated transcriptional activation of cAMP response element-binding proteins; CRL4B: Cullin 4B-RING E3 ubiquitin ligase; eWAT: epididymal white adipose tissue; FOXA3: forkhead box protein A3; HBP: hexosamine biosynthesis pathway; HDAC: histone deacetylase; HFD: high-fat diet; hTERT: human telomere reverse transcriptase; JAK/STAT: Janus kinase/signal transducer and activator of transcription; MAPK: mitogen-activated protein kinase; MARCH5: membrane-associated RING-CH-type finger 5; MDM2: murine double minute 2; MKRN1: makorin ring finger protein 1; MYF5: myogenic factor 5; NAD: nicotinamide adenine dinucleotide; NAMPT: nicotinamide phosphoribosyltransferase; NEDD4: neural precursor cell–expressed developmentally downregulated protein 4; NF-κB: nuclear factor kappa B; OGA: O–GlcNAcase; O-GlcNAc: O-linked-β-N-acetyl-

glucosamine; O-GlcNAcylation: O-linked-N-acetylglucosamination; OGT: O-GlcNAc transferase; p27: p27Kip1; PGC-1α: PPAR-g coactivator 1-alpha; PI3K/AKT: phosphatidylinositol 3-kinase/protein kinase B; PPARγ: peroxisome proliferator-activated receptor γ; PRDM16: PR domain-containing 16; PTEN: phosphatase and tensin homolog on chromosome 10; PTM: post-translational modifications; RB: retinoblastoma protein; ROC1: regulator of cullins-1; SA-β-gal: senescence-associated-β-galactosidase; SASP: senescence-associated secretory phenotype; SIRT: sirtuin; STEAP4: six-transmembrane epithelial antigen of prostate 4; SVF: stromal vascular fraction; TG: triglyceride; TRIM23: tripartite motif protein 23; TSA: trichostatin A; UCP1: uncoupling protein-1; UPP: ubiquitin-proteasome pathway; WAT: white adipocyte; WWP1: WW domain-containing E3 ubiquitin protein ligase 1; ZBTB7C: zinc finger and BTB domain-containing 7C.

📖 中文全文 Chinese Full Text

中文

# 蛋白质翻译后修饰在脂肪细胞衰老中的作用

黄敏善1、朴静英2、咸允河2、李仁惠2,*、全庆熙1,*

1. 延世大学医学院生物化学与分子医学系,医学科学研究院,BK21项目,遗传科学研究所,韩国首尔西大门区延世路50-1,03722 2. 梨花女子大学自然科学学院生命科学系,韩国首尔西大门区梨花女大路52,03760

*通讯作者:李仁惠博士,梨花女子大学自然科学学院生命科学系,韩国首尔西大门区梨花女大路52,03760。电话:+82-2-3277-3032,电子邮箱:lih3026@ewha.ac.kr。全庆熙博士,延世大学医学院生物化学与分子医学系,韩国首尔西大门区延世路50-1,03722。电话:+82-2-2228-1699,传真:+82-2-312-5041,电子邮箱:khchun@yuhs.ac。

© 作者。本文根据知识共享署名许可协议(https://creativecommons.org/licenses/by/4.0/)的条款进行开放获取分发。完整条款和条件参见http://ivyspring.com/terms。

收稿日期:2023.05.22;接受日期:2023.09.27;发表日期:2023.10.16

## 摘要

脂肪细胞是通过脂质为机体提供能量的脂肪组织。脂肪细胞主要包括两种类型:储存能量的白色脂肪细胞(WAT)和通过燃烧储存的脂肪产生热量的棕色脂肪细胞(BAT,即产热作用)。新出现的证据表明,脂肪细胞衰老的失调可能破坏代谢稳态,导致多种疾病和衰老。脂肪细胞在DNA损伤、氧化应激、端粒功能障碍或慢性脂质积累导致的脂肪细胞过度扩张等刺激下,通过不可逆的细胞周期阻滞进入衰老状态。可检测到的BAT数量随年龄增长而减少。细胞周期调节因子的激活和脂肪生成调节因子的失调可能构成加速脂肪细胞衰老的分子机制。为了更好地理解脂肪细胞衰老的调控,研究翻译后修饰(PTMs)对阐明这些蛋白质的活性和稳定性至关重要。PTMs是蛋白质生物合成后引入的共价酶促蛋白质修饰,如磷酸化、乙酰化、泛素化或糖基化。确定PTMs对脂肪细胞衰老的贡献可能为调控脂肪细胞衰老提供新的治疗靶点。在本综述中,我们讨论了PTMs调控脂肪细胞衰老的概念性案例,并解释了蛋白质调控的机制,这可能为开发对抗代谢疾病的有效策略提供依据。

**关键词:** 脂肪细胞,衰老,翻译后修饰,代谢疾病,代谢稳态

## 引言

脂肪生成是前脂肪细胞分化为成熟脂肪细胞过程中的关键过程。脂肪细胞增殖形成脂肪组织,其中从食物中获取的能量超过能量消耗的部分以脂质形式储存。前脂肪细胞经历四个阶段发育:生长阻滞、有丝克隆扩增、早期分化和终末分化为成熟脂肪细胞[1]。在此过程中,前脂肪细胞通过增加甘油三酯(TG)合成所需酶的数量和TG的积累来积累脂质。转录因子如过氧化物酶体增殖物激活受体γ(PPARγ)、CCAAT/增强子结合蛋白α(C/EBPα)和CCAAT/增强子结合蛋白β(C/EBPβ)的表达增加对脂肪细胞分化至关重要[2](图1A)。PPARγ是脂肪生成的重要调节因子,C/EBP家族(α和β)是PPARγ最关键的下游靶点之一。这些蛋白质对于成熟脂肪细胞中胰岛素受体、脂联素、脂肪细胞蛋白2(aP2)和脂肪因子的转录和表达也是必需的[3, 4]。

理解脂肪细胞衰老及其调控所涉及的过程至关重要。脂肪细胞衰老代表对各种应激源(包括DNA损伤、氧化应激、代谢应激和端粒缩短)的不可逆细胞周期阻滞[5, 6](图1B)。这些应激源通过多种途径传递信号,其中大多数激活细胞周期抑制因子p53。这些途径汇聚于细胞周期蛋白依赖性激酶(CDK)抑制因子p16、p21、p27和p15的激活。最终,它们激活视网膜母细胞瘤蛋白(RB),导致衰老[7]。未修复的DNA损伤和修复能力的丧失可诱导衰老[8]。在脂肪组织中,p53有助于年龄相关代谢疾病中的胰岛素抵抗。过量热量摄入加剧氧化应激,并增加脂肪组织中p53和促炎细胞因子的产生。相反,脂肪组织中p53的抑制通过减少促炎细胞因子和改善胰岛素敏感性来减轻衰老样变化[9]。有趣的是,PPARγ控制脂肪细胞分化、抑制细胞增殖并促进细胞衰老[10, 11]。PPARγ诱导细胞周期抑制因子p16INK4α(CDKN2A)的表达,p16INK4α促进衰老,增加衰老相关-β-半乳糖苷酶(SA-β-gal)水平,并触发G1期阻滞[11]。细胞衰老导致脂肪来源的基质/祖细胞中脂肪生成和脂质储存的功能障碍[12](图1C)。

脂肪组织的褐变(或称米色化)是指白色脂肪细胞(WAT)转化为棕色样脂肪细胞,如米色或brite细胞的过程(图2)。棕色脂肪细胞(BAT)具有产热作用,意味着它们通过燃烧储存的脂肪产生热量。脂肪组织褐变通常与能量消耗增加和代谢健康改善相关。负责能量产生的BAT比提供能量储存的WAT含有更多的线粒体[13]。在发育上,在小鼠中,BAT起源于生肌因子5(MYF5)阳性中胚层谱系[14](图2A)。BAT特异性产热程序的转录控制由PPAR-γ共激活因子1-α(PGC-1α)和含PR结构域的16(PRDM16)介导[15](图2B)。众所周知,BAT依赖线粒体功能维持细胞内代谢。此外,BAT线粒体由解偶联蛋白-1(UCP1)功能化,UCP1允许质子转位以在非颤抖性产热过程中耗散能量[16, 17](图2B)。叉头盒蛋白A3(FOXA3)的表达在衰老期间内脏脂肪中增加,据报道可减少BAT质量和WAT的米色化能力[18, 19]。在衰老的背景下,据报道老年小鼠脂肪组织中线粒体酶表达降低,但关于介导这些变化的机制知之甚少[20, 21]。同样,众所周知,人类WAT线粒体功能(通过组织耗氧量测量)在肥胖和衰老中均降低[21]。与此一致,Foxa3基因敲除小鼠寿命更长,晚年BAT活性增加,并且对年龄相关胰岛素抵抗和高脂饮食诱导的内脏脂肪增加具有保护作用[19](图2C)。

有证据表明,BAT的复制能力和UCP1表达在衰老期间显著降低[16, 17]。特别是,老年BAT中对冷刺激的增殖能力和UCP1表达似乎被消除[22]。brite脂肪细胞年龄的增长逐渐导致WAT表型的形成,这阻止了老年小鼠和人类的脂肪细胞褐变[23, 24]。相反,衰老标志物p16和p21的水平在BAT衰老过程中高度增加[13, 25]。BAT产热随年龄增长而下降[26](图2D),与产热因子UCP1的减少一致,而BAT中UCP1水平通过SIRT5去琥珀酰化而稳定。BAT中Sirt5缺乏增加UCP1的琥珀酰化,导致UCP1稳定性和功能降低,从而损害线粒体稳态并改变BAT介导的产热[27]。因此,这可能是调控BAT衰老的机制之一。

衰老细胞积累的一些有害影响已有报道,包括炎症、脂肪组织中的胰岛素抵抗、潜在的肥胖和2型糖尿病[6, 7, 9, 28]。衰老相关分泌表型(SASP)包括促炎细胞因子,通过自分泌和旁分泌途径产生,以增强和扩散衰老细胞的影响并诱导脂肪组织中的慢性炎症[29]。在应激刺激条件下,这些交互信号通路汇聚于核因子κB(NF-κB)和C/EBPβ管理的转录程序的激活,NF-κB和C/EBPβ是启动和维持SASP基因表达的核心效应因子[30]。去除衰老脂肪细胞减轻炎症并改善脂肪组织中的胰岛素抵抗[29]。因此,适当控制脂肪细胞衰老对于管理各种疾病至关重要。

控制细胞衰老的机制可分为三类。这些包括遗传和表观遗传水平的转录修饰,如DNA甲基化;mRNA水平的调控机制,如mRNA稳定或降解;以及翻译后修饰(PTMs),如泛素化[31]。在此,我们重点关注调控蛋白质稳定性和激活的PTMs。磷酸化、乙酰化、泛素化和糖基化等PTMs改变蛋白质的化学性质和功能[32]。异常的PTMs可导致生物功能障碍并导致各种疾病。例如,PTMs显著影响调控脂肪细胞衰老的蛋白质的结构和功能。理解PTMs在脂肪细胞衰老中的作用可能指导发现调节脂肪细胞衰老的新治疗靶点。在本综述中,我们总结了参与脂肪细胞衰老诱导的蛋白质的稳定性和激活如何被各种PTMs调控(表1),并提供了关于脂肪细胞衰老调控的新见解(图3)。

**表1. 脂肪细胞衰老中翻译后修饰(PTM)的总结**

| PTM | 底物 | 通路 | 作用位点 | |------|------|------|----------| | 磷酸化 | p38 MAPK[40-42] | SASP/JAK/STAT通路 | IRS-2 | | 去磷酸化 | PTEN[49-51] | p38 MAPK信号通路/PIP3/PI3K/AKT信号通路 | — | | 去乙酰化 | SIRT1[57,58,62] | PPARγ/脂生成/p27Kip1/脂肪细胞分化 | Lys268和Lys293 | | | SIRT6[64] | H3K27/产热/p14ARF, AMPKα/脂肪酸氧化 | Lys100 | | | HDAC1[70, 72] | PPARγ/脂肪细胞分化 | Lys27 | | 泛素化 | MKRN1[83-85] | PPARγ/脂肪细胞分化 | — | | | TRIM23[86] | — | — | | | TRIM25[87] | — | — | | | MARCH 5[88] | 糖酵解和基础线粒体呼吸 | — | | | CRL4B[90] | PPARγ | — | | | MDM2[92] | STEAP4 | — | | | WWP1[94] | p27Kip1 | — | | O-GlcNAc糖基化 | OGT, OGA[97, 100,102] | PPARγ/HBP通量[103,104]/C/EBPβ/AMPKα/HIF1-α/PKM2信号通路/脂肪细胞分化 | Thr54(N端激活功能-1结构域)/Ser180和Ser181 |

## 磷酸化对蛋白质激活的调控

脂肪细胞衰老受到严格调控以维持能量和代谢稳态[26]。衰老细胞在复制性、细胞因子诱导的和代谢应激下在衰老脂肪中积累[33]、Janus激酶(JAK)、p38和10号染色体上缺失的磷酸酶和张力蛋白同源物(PTEN)在各种细胞应激条件下上调脂肪细胞衰老。已知细胞磷酸化可增强或下调脂肪细胞衰老;然而,其潜在机制需要进一步研究。

### JAK

对应激源(内在或外在)的细胞衰老增加和广泛相关的SASP促进机体衰老和脂肪组织功能障碍[26, 34, 35]。抑制JAK/信号转导子和转录激活子(JAK/STAT)通路(该通路在脂肪组织发育和功能中起重要作用并调节SASP)可部分抑制SASP分泌[34, 36]。JAK1/2抑制剂芦可替尼在体外和体内降低促炎SASP并增强衰老小鼠的胰岛素敏感性[34]。衰老细胞改善增强脂肪生成和代谢[37, 38]。衰老细胞分泌的激活素A阻断脂肪生成。用JAK抑制剂治疗老年小鼠和原代人衰老脂肪祖细胞降低了激活素A水平并恢复了脂质积累和关键脂肪生成标志物的表达。JAK抑制剂还降低脂毒性并增加胰岛素敏感性[37]。抑制JAK活性是通过改善衰老脂肪祖细胞和干细胞(APSCs)来减轻脂肪细胞衰老的策略。

### p38 MAPK

SASP被p38丝裂原活化蛋白激酶(MAPK)的激活所增强,p38 MAPK由NF-κB转录活性增加诱导。p38 MAPK抑制显著减少了大多数SASP因子的分泌[34, 39]。SASP导致衰老器官功能障碍。与年龄相关的脂肪组织变化增加促炎细胞因子,如肿瘤坏死因子α(TNF-α),促进脂肪细胞衰老[3, 35, 40],从而减少棕色脂肪生成分化并促进BAT中的胰岛素抵抗。在此细胞事件中,p38 MAPK磷酸化胰岛素受体底物2(IRS-2)的丝氨酸残基[40-42]。抑制p38 MAPK减少SASP分泌,这可能改善脂肪细胞衰老。

### PTEN

胰岛素信号反应对脂肪细胞中的细胞衰老表现出更高的敏感性,从而降低胰岛素反应[6, 26, 43, 44]。PTEN是一种磷脂酰肌醇磷酸酶,在各种细胞过程中发挥重要作用,包括基因组维持、DNA修复、细胞周期控制、增殖、代谢、迁移、肿瘤发生和衰老。PTEN的关键作用之一是抑制胰岛素信号[45-48]。PTEN通过使磷脂酰肌醇-3,4,5-三磷酸(PIP3)去磷酸化来负调控胰岛素信号,导致磷脂酰肌醇3-激酶/蛋白激酶B(PI3K/AKT)信号减少[49]。Pten缺乏增强棕色脂肪组织的能量消耗。PTEN缺失和PI3K/AKT信号激活导致小鼠处理代谢应激的能力改善[50]。PTEN下调增加脂肪组织中基质血管组分(SVF)细胞(包括脂肪细胞祖细胞)的增殖。Pten缺乏恢复高传代SVF细胞的分化能力并增加脂肪生成。相反,PTEN表达在细胞衰老期间上调[51]。调控PTEN活性和表达水平是控制脂肪细胞衰老的策略。

## 乙酰化对蛋白质激活的调控

PPARγ直接与SIRT1表达相互作用并负调控其表达[10]。与Sirt1缺乏相关的PPARγ乙酰化在细胞衰老期间增加[10]。SIRT1通过c-Myc去乙酰化限制前脂肪细胞增生,通过抑制PPARγ改善胰岛素敏感性、减少炎症并抑制脂质积累[57]。原癌蛋白锌指和BTB结构域含7C(ZBTB7C)负调控Sirt1转录水平。其在衰老小鼠WAT中的表达水平增加。ZBTB7C作为强效SIRT1抑制因子,增加PPARγ乙酰化[58]。烟酰胺磷酸核糖转移酶(NAMPT)的表达在细胞衰老期间增加,NAMPT回收NAD+。NAMPT活性促进促炎SASP[34, 59-61]。SIRT1活性随年龄相关的降低可能是米色脂肪组织丢失以及年龄相关产热受损的关键机制[26]。上调SIRT1通过PPARγ在Lys268和Lys293的去乙酰化增强皮下WAT的棕色重塑[62]。SIRT1调控可能是控制脂肪细胞衰老的关键机制。

衰老脂肪细胞在细胞因子和代谢应激下在衰老脂肪中积累[26, 33]。脂肪细胞衰老在冷暴露刺激的产热反应中受到调控。脂肪细胞中与产热相关的线粒体蛋白UCP-1的线粒体功能和活性随细胞衰老而降低。此外,BAT的促炎能力随年龄增加[26, 35, 52]。组蛋白去乙酰化酶(HDACs)如sirtuin 1(SIRT1)、SIRT6和HDAC1是细胞应激条件下脂肪细胞衰老的重要调节因子[26, 53, 54]。尽管SIRTs和HDAC1都是去乙酰化酶,但它们在脂肪细胞衰老中的作用不同。SIRT1和SIRT6防止脂肪细胞衰老,而HDAC1增强脂肪细胞衰老。棕色和米色脂肪细胞的数量随年龄减少。细胞去乙酰化事件调控脂肪细胞衰老。然而,其潜在机制仍不清楚。

### SIRT1

在衰老脂肪组织中检测到米色脂肪细胞形成减少[26]。SIRT1是一种烟酰胺腺嘌呤二核苷酸(NAD+)依赖性去乙酰化酶,驱动WAT中米色脂肪细胞的生成[26]。此外,NAD+水平、SIRT1活性和SIRT1表达随年龄和细胞衰老进展而降低[10, 55, 56]。

### SIRT6

SIRT6在脂肪细胞中的基本作用是脂质代谢调控和炎症预防。SIRT6刺激脂肪分解,增强脂肪组织褐变,并改善脂肪组织炎症,从而改善外周组织中的胰岛素作用[63]。SIRT6促进细胞增殖并拮抗细胞衰老;然而,SIRT6表达在细胞衰老期间减少[64]。此外,SIRT6在细胞衰老期间抑制p27Kip1(p27)表达[64]。SIRT6介导p27的多聚泛素化,引导其被蛋白酶体降解,从而调控p27的乙酰化状态。因此,SIRT6延缓细胞衰老[64]。衰老和过量热量摄入是肥胖和糖尿病的两个主要危险因素,导致SIRT6水平降低[65]。前脂肪细胞中Sirt6缺乏阻断脂肪生成并调控有丝克隆扩增[66]。脂肪组织中Sirt6缺失损害BAT的产热功能,导致棕色脂肪形态学"白化"、耗氧量减少、肥胖、核心体温降低和冷敏感性。脂肪Sirt6缺失小鼠表现出血糖水平升高、严重胰岛素抵抗和肝脏脂肪变性。此外,Sirt6缺乏抑制冷暴露或β3-激动剂治疗后WAT的褐变[67]。总之,这些结果表明SIRT6对脂肪细胞衰老起保护作用。

### HDAC1

使用HDAC抑制剂(包括曲古抑菌素A(TSA))抑制诱导SASP的信号通路可抑制衰老。在低浓度下,TSA作为泛SASP阻断剂[34, 68]。TSA可降低PPARγ表达[53, 69],增强细胞衰老。HDAC抑制剂还参与调控产热脂肪细胞分化、适应性产热和代谢疾病发病机制[70]。HDAC1在衰老细胞中高表达[71]。HDAC1负调控BAT中的产热程序。抑制HDAC1促进组蛋白H3K27的乙酰化并阻止其甲基化,从而增加BAT特异性基因如UCP1、PGC-1α和PRDM16的表达[70, 72]。SIRT1负调控HDAC1功能[54, 73]。SIRT1在细胞衰老期间被降解和下调[56, 74],表明Sirt1缺乏可能增加衰老细胞中HDAC1活性[54]。因此,调控HDAC1功能可能改善脂肪细胞衰老。

## 泛素化对蛋白质稳定性的调控:E3泛素连接酶

影响生理性细胞衰老的另一种调控机制是通过泛素化对细胞蛋白质进行翻译后修饰。泛素-蛋白酶体途径(UPP)调控各种细胞类型的分化。成熟脂肪细胞中UPP的改变可能调控脂肪细胞衰老期间的脂肪功能[75]。泛素被E1激活并转移至E2或泛素结合酶。反过来,E2酶将泛素转移至E3或与E3一起直接泛素化靶蛋白[72, 73]。蛋白酶体活性在衰老期间降低,这可能与衰老和年龄相关疾病相关[75]。E3泛素-蛋白连接酶是通过泛素化调控衰老的关键因子。敲低cullins调节因子-1(ROC1)(SKP、Cullin、F-box(SCF)E3泛素连接酶的组分)通过诱导衰老抑制几种人类细胞系的生长[76]。此外,von Hippel–Lindau(VHL)肿瘤抑制基因(编码E3泛素连接酶的亚基)的失活导致人类癌细胞系中的衰老样表型[77]。因此,E3泛素连接酶活性似乎对调控脂肪细胞衰老至关重要。最近发现几种E3连接酶存在于脂肪细胞中,包括seven in absentia同源物2(SIAH2)、makorin环指蛋白1(MKRN1)、三基序蛋白23(TRIM23)和神经前体细胞表达发育下调蛋白4(NEDD4)[78]。泛素化途径调控正常细胞中p53肿瘤抑制因子的稳定性、定位和功能[79]。E3泛素连接酶,包括鼠双微体2(MDM2)和MKRN1,主要在各种生理条件下调控p53表达水平和活性[79, 80]。MDM2和CDM4的过表达可诱导人2H转基因骨髓-间充质干细胞(BM-MSCs)中人端粒酶逆转录酶(hTERT)过表达和p53降解,增加细胞增殖和迁移,并抑制体外脂肪生成分化潜能[81]。

### MKRN1

在端粒酶阳性细胞中,E3连接酶MKRN1的过表达促进hTERT降解,降低端粒酶活性,随后降低端粒长度[82]。MKRN1敲低通过稳定p14ARF诱导衰老。MKRN1还调控SASP[83]。MKRN1通过泛素介导的蛋白酶体降解负调控PPARγ,PPARγ2和MKRN1直接相互作用[84]。MKRN1还泛素化并降解AMP活化蛋白激酶α(AMPKα)亚基,而MKRN1缺失通过AMPK稳定和激活促进葡萄糖消耗并抑制脂质积累[85]。这些结果表明E3连接酶MKRN1可能调控脂肪细胞衰老,值得进一步研究。

### TRIM23和TRIM25

TRIM23是一种E3连接酶,可调控PPARγ蛋白稳定性并介导异常的多聚泛素结合[86]。TRIM23是形成晚期增强体和在晚期脂肪生成分化期间招募Pol II所必需的,而用蛋白酶体抑制剂MG132处理抑制了TRIM23敲低细胞中PPARγ的减少[86]。26S蛋白酶体不易识别被TRIM23异常泛素化的PPARγ,从而保护其免受蛋白酶体降解[86]。然而,TRIM25直接诱导PPARγ泛素化及其蛋白酶体依赖性降解[87]。TRIM25降低PPARγ表达并抑制3T3-L1脂肪细胞分化[87]。因此,TRIM25表达与PPARγ表达呈负相关。

### MARCH 5

E3泛素连接酶膜相关RING-CH型指5(MARCH 5)调控线粒体动力学,并反过来被经历脂肪生成的脂肪细胞中的PPARγ调控[88]。MARCH 5缺失增加糖酵解和基础线粒体呼吸[88]。MARCH5缺陷细胞由于细胞衰老引起的SA-β-Gal表达增加而显示线粒体延长和表型变化[89]。

### CRL4B

芳烃受体(AhR)通过蛋白酶体依赖性机制降低PPARγ蛋白稳定性[90]。在3T3-L1细胞中过表达AhR诱导内源性PPARγ降低,这被MG132处理逆转[90]。AhR作为Cullin 4B-RING E3泛素连接酶(CRL4B)AhR复合物中的底物受体,诱导PPARγ的多聚泛素化[90]。

### MDM2

E3泛素连接酶MDM2通过促进cAMP介导的cAMP反应元件结合蛋白(CREB)的转录激活和诱导C/EBPδ表达来调控脂肪生成,从而启动脂肪细胞分化[91]。高脂饮食(HFD)喂养的Mdm2-脂肪细胞特异性敲入(Mdm2-AKI)小鼠表现出附睾白色脂肪组织(eWAT)功能障碍,包括衰老[92]。MDM2通过泛素修饰抑制六次跨膜前列腺上皮抗原4(STEAP4)表达[92]。STEAP4的恢复挽救了HFD喂养的Mdm2-AKI小鼠eWAT中MDM2诱导的脂肪功能障碍[92]。

### WWP1

肥胖上调WAT中含WW结构域的E3泛素蛋白连接酶1(WWP1)。WWP1属于NEDD4样E3泛素连接酶家族,在肥胖WAT中上调[93]。WWP1通过泛素化诱导p27Kip1降解并抑制p27Kip1介导的复制性衰老[94]。WWP1过表达降低3T3-L1细胞中的活性氧(ROS)水平,并且WWP1保护脂肪细胞和WAT免受肥胖相关氧化应激[95]。

## O-GlcNAc糖基化对蛋白质激活的调控

O-连接-N-乙酰氨基葡萄糖糖基化(O-GlcNAcylation)是一种翻译后糖基化事件,发生在细胞核、细胞质和线粒体中的蛋白质上,调控细胞信号传导,并与多种病理状况相关[96]。O-GlcNAcylation是将O-连接-β-N-乙酰氨基葡萄糖(O-GlcNAc)单糖添加到靶蛋白丝氨酸或苏氨酸残基的羟基上[97]。O-GlcNAc在蛋白质上的连接和去除由O-GlcNAc转移酶(OGT)和O-GlcNAcase(OGA)处理[98]。O-GlcNAcylation对葡萄糖高度敏感,胰岛素抵抗增强O-GlcNAcylation[99]。在诱导脂肪细胞分化后观察到O-GlcNAcylation水平增加[100]。翻译后修饰调控OGT活性,在3T3-L1细胞中胰岛素刺激后OGT酪氨酸磷酸化增加时发生OGT激活[101]。异常的蛋白质O-GlcNAcylation对衰老相关疾病的发展和进展至关重要[102]。

在3T3-L1分化诱导的第5天及之后,O-GlcNAcylation水平显著增加[100]。同时,C/EBPα和脂联素表达以及脂滴大小增加[100]。波形蛋白、长链脂肪酸-CoA和丙酮酸羧化酶的O-GlcNAcylation随脂肪细胞分化而增加[100]。用6-重氮-5-氧代-正亮氨酸(DON)(一种谷氨酰胺:果糖-6-磷酸氨基转移酶(GFAT)抑制剂)处理在C/EBPα表达阶段阻断脂肪细胞分化,这与O-GlcNAcylation的整体增加相关[100]。因此,可以假设O-GlcNAcylation部分参与脂肪生成。

在3T3-L1脂肪细胞中,O-GlcNAc引起PPARγ的转录后修饰。PPARγ的主要O-GlcNAc位点是N端激活功能-1结构域的苏氨酸54[97]。在3T3-L1细胞中,通过OGA抑制剂NButGT介导的O-GlcNAc修饰增加降低PPARγ转录活性和终末脂肪细胞分化[97]。

C/EBPβ也被O-GlcNAc修饰,O-GlcNAc存在于核质蛋白中。GlcNAcylation位点(Ser180和Ser181)位于调控结构域中,极其接近调控DNA结合活性的磷酸化位点(Thr188、Ser184和Thr179)[102]。Ser180和Ser181的GlcNAcylation阻断Thr188、Ser184和Thr179的磷酸化,从而延迟脂肪细胞分化[102]。相反,Ser180和Ser181突变为Ala增加C/EBPβ转录活性[102]。因此,GlcNAcylation和磷酸化似乎通过交替占据相邻位点来调控C/EBPβ的功能。

己糖胺生物合成途径(HBP)通量作为营养传感器发挥作用,并在永生化和小鼠原代脂肪细胞中诱导AMPK α亚基的O-GlcNAc修饰[103]。通过HBP通量的O-连接糖基化调控AMPK激活并诱导3T3-L1脂肪细胞中的脂肪酸氧化[104],而通过氨基己糖苷酶去除O-GlcNAc降低AMPK活性[104]。因此,HBP与O-GlcNAc相关并可能影响脂肪细胞衰老。

## 结论与展望

脂肪生成是前脂肪细胞分化为成熟脂肪细胞的过程。含有脂质的脂肪细胞主要有两种类型:储存能量的WAT和产生热量的BAT。前脂肪细胞经历四个阶段发育:生长阻滞、有丝克隆扩增、早期分化和终末分化为成熟脂肪细胞[1]。在此过程中,转录因子的表达增加对脂肪细胞分化至关重要[2](图1A)。

在DNA损伤、氧化应激、代谢应激或端粒缩短时,脂肪细胞经历衰老和不可逆的细胞周期阻滞,从而抑制脂肪生成[5, 6]。这些细胞应激源激活p53并诱导CDK抑制因子和RB,导致衰老[7]。此外,脂肪生成调节因子如PPAR和C/EBPα/β的修饰导致脂肪细胞衰老。此外,据报道老年小鼠脂肪细胞中线粒体UCP1表达降低;然而,关于这一机制知之甚少[16, 17, 27]。随着BAT衰老过程中UCP1水平降低,衰老标志物p16和p21水平显著增加[13, 25]。此外,BAT中产热因子UCP1的表达通过SIRT5去琥珀酰化而稳定。因此,这可能是调控BAT衰老的机制;然而,这种可能性需要进一步研究。

一旦脂质在脂肪组织中持续积累,脂肪细胞衰老率增加,胰岛素敏感性降低,导致脂肪组织功能障碍。SASP诱导脂肪组织中的慢性炎症。细胞衰老导致脂质储存功能障碍。因此,适当控制脂肪细胞衰老是预防衰老相关疾病的可行策略。尽管潜在机制仍然知之甚少,但脂肪细胞衰老对于多种生理过程(包括代谢和各种年龄相关疾病)至关重要。为了更好地理解脂肪细胞衰老的过程,鉴定脂肪生成因子(包括PPARγ)的调控因子及其调控分子机制(如PTMs)非常重要。PTMs与氧化应激、炎症和衰老相关,从而影响衰老特征[105]。一些PTMs参与健康衰老,表明它们是衰老过程的关键调控因子和预测标志物[106]。PTMs显著影响

# 翻译

因此,靶向表观遗传和非表观遗传通路来延缓衰老具有重要意义。因此,理解翻译后修饰(PTMs)在细胞衰老中的作用可能推动针对衰老相关疾病的靶向治疗的发展。

在应激条件下,p38、JAK和PTEN通过磷酸化影响脂肪细胞衰老(图3)。抑制JAK/STAT通路可抑制SASP分泌,而Pten缺陷则促进脂肪生成[34, 36-39]。

SIRT1诱导白色脂肪组织(WAT)中米色脂肪细胞的生成[107]。PPARγ与SIRT1直接相互作用,负调控SIRT1的表达[10]。挽救NAD+的NAMPT活性可促进SASP。SIRT6还在细胞衰老过程中抑制p27的表达,从而减缓这一过程[34, 59-61]。SIRT1和SIRT6的调控被认为是控制脂肪细胞衰老的关键机制[63-65, 67]。抑制SASP通路可抑制衰老。HDAC1在衰老细胞中高表达。调控HDAC1功能可能延缓脂肪细胞衰老(图3)。

肿瘤抑制基因的失活可导致与衰老过程中观察到的相似表型[77]。因此,E3泛素连接酶活性似乎对脂肪细胞衰老的调控至关重要。MKRN1可能通过泛素化负调控PPARγ[84]。由于TRIM25降低PPARγ表达并抑制3T3-L1脂肪细胞的分化,TRIM25与PPARγ表达呈负相关[87]。MARCH5缺失可增加糖酵解和基础线粒体呼吸[88]。此外,E3泛素连接酶的组分如ROC1、TRIM23、CRL4B、WWP1和MDM2可抑制脂肪细胞衰老[76, 86, 90, 92, 95]。

O-GlcNAc糖基化调控细胞信号传导,在衰老相关疾病的发展和进展中发挥重要作用。OGT和OGA分别调控O-GlcNAc的连接和去除。在3T3-L1细胞中,这些酶诱导脂肪细胞衰老。我们预测,通过理解PTMs在脂肪细胞衰老中的参与,可以开发针对脂肪细胞衰老的新疗法(图3)。

特别需要更清楚地理解PTMs(包括乙酰化/去乙酰化、磷酸化、泛素化和糖基化)如何调控必要脂肪生成因子(如PPAR)的功能(图3)。最后,重要的是确定在多种疾病状态下,预防脂肪细胞衰老在多大程度上介导了对脂肪组织的有益影响。未来对脂肪细胞衰老调控机制的研究可能为人类生物学过程(包括衰老和代谢)中涉及的新而复杂的网络提供关键见解。

https://www.ijbs.com

**图3. 翻译后修饰(PTM)对脂肪细胞衰老的调控。** PTM通过多种生理通路调控脂肪细胞衰老,包括磷酸化、去乙酰化、泛素化和糖基化。抑制p38、JAK和PTEN可缓解脂肪细胞衰老。去乙酰化也调控脂肪细胞衰老。SIRT1和SIRT6是去乙酰化酶,在对抗脂肪细胞衰老中发挥保护作用。SIRT1负调控在衰老细胞中高表达的HDAC1。TRIM23和MDM2是诱导脂肪细胞衰老的E3泛素连接酶。然而,ROC1抑制细胞衰老。E3泛素连接酶MKRN1、MARCH5、TRIM25、CRL4B和WWP1也是脂肪细胞衰老的潜在调控因子。OGT和OGA调控O-GlcNAc糖基化。异常的蛋白质O-GlcNAc糖基化导致衰老相关疾病。

**缩写词**

AhR:芳香烃受体;AMPK:AMP活化蛋白激酶;aP2:脂肪细胞蛋白2;BAT:棕色脂肪细胞;CDK:细胞周期蛋白依赖性激酶;C/EBPα/b:CCAAT/增强子结合蛋白α/b;CREB:cAMP介导的cAMP反应元件结合蛋白的转录激活;CRL4B:Cullin 4B-RING E3泛素连接酶;eWAT:附睾白色脂肪组织;FOXA3:叉头框蛋白A3;HBP:己糖胺生物合成通路;HDAC:组蛋白去乙酰化酶;HFD:高脂饮食;hTERT:人端粒逆转录酶;JAK/STAT:Janus激酶/信号转导及转录激活因子;MAPK:丝裂原活化蛋白激酶;MARCH5:膜相关RING-CH型指蛋白5;MDM2:鼠双微体2;MKRN1:Makorin环指蛋白1;MYF5:肌源性因子5;NAD:烟酰胺腺嘌呤二核苷酸;NAMPT:烟酰胺磷酸核糖基转移酶;NEDD4:神经前体细胞表达发育下调蛋白4;NF-κB:核因子κB;OGA:O-GlcNAc水解酶;O-GlcNAc:O-连接-β-N-乙酰氨基葡萄糖;O-GlcNAc糖基化:O-连接-N-乙酰氨基葡萄糖基化;OGT:O-GlcNAc转移酶;p27:p27Kip1;PGC-1α:PPAR-γ共激活因子1-α;PI3K/AKT:磷脂酰肌醇3-激酶/蛋白激酶B;PPARγ:过氧化物酶体增殖物激活受体γ;PRDM16:含PR结构域蛋白16;PTEN:第10号染色体上缺失的磷酸酶及张力蛋白同源物;PTM:翻译后修饰;RB:视网膜母细胞瘤蛋白;ROC1:Cullin调节因子-1;SA-β-gal:衰老相关-β-半乳糖苷酶;SASP:衰老相关分泌表型;SIRT:Sirtuin蛋白;STEAP4:前列腺六次跨膜上皮抗原4;SVF:基质血管组分;TG:甘油三酯;TRIM23:三方基序蛋白23;TSA:曲古抑菌素A;UCP1:解偶联蛋白-1;UPP:泛素-蛋白酶体通路;WAT:白色脂肪细胞;WWP1:含WW结构域E3泛素蛋白连接酶1;ZBTB7C:锌指和BTB结构域含蛋白7C。